Real-World Data Study Supports Use of Paxlovid for COVID-19 in High-Risk Patients

A newly-published real-world study in the Journal of the American College of Clinical Pharmacy finds new data supporting the use of Paxlovid in high-risk COVID-19 patients. The retrospective study followed patients administered the combination therapy at a single medical center, finding that the drug was well-tolerated and helped improve health outcomes for people at-risk for severe COVID-19.

According to Rose McNulty, “None of the patients died or were hospitalized within 28 days of therapy initiation. The 58 patients with available records completed the course of therapy without significant issues. Two patients experienced rebound disease symptoms and tested positive for COVID-19 again within 28 days of treatment initiation, but neither required hospitalization. The most common adverse events were cough, chest discomfort, migraines, and nausea.”

To read more, click here.

(Source: AJMC, November 23^rd, 2022)